Evidence map›Paper›PMID 39928571›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2025

Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial.

Gary A Wittert, Kristy P Robledo, David J Handelsman, Warrick J Inder, Bronwyn G A Stuckey, Bu B Yeap, Karen Bracken, Carolyn A Allan, David Jesudason, Alicia Jenkins and 2 more

Erratum issuedAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Gary A WittertFreemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA 5000, Australia.ORCID 0000-0001-6818-6065
Kristy P RobledoNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia.
David J HandelsmanANZAC Research Institute, University of Sydney and Department of Andrology, Concord Hospital, Sydney, NSW 2139, Australia.
Warrick J InderDepartment of Endocrinology, Princess Alexandra Hospital and the University of Queensland, Brisbane, QLD 4102, Australia.ORCID 0000-0001-5078-4980
Bronwyn G A StuckeyKeogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital and Medical School, University of Western Australia, Nedlands, WA 6009, Australia.
Bu B YeapMedical School, University of Western Australia and Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, WA 6150, Australia.ORCID 0000-0002-7612-5892
Karen BrackenSydney Musculoskeletal Health, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia.
Carolyn A AllanCentre for Endocrinology and Metabolism, Hudson Institute of Medical Research, School of Clinical Sciences at Monash Health, and Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.
David JesudasonFreemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA 5000, Australia.
Alicia JenkinsDiabetes and Vascular Medicine, Baker Heart and Diabetes Institute, Melbourne, Melbourne, VIC 3074, Australia.
Andrzej S JanuszewskiSydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Canperdown, NSW 2050, Australia.
Mathis GrossmannDepartment of Medicine and Endocrinology, Austin Health, and University of Melbourne, Heidelberg, VIC 3079, Australia.ORCID 0000-0001-8261-3457

Funding

BayerLillyNational Health and Medical Research Council 1030123Sonic HealthcareUniversity of AdelaideWeight Watchers
6 · The paper itself

Abstract

contextThe combined effects of testosterone treatment and lifestyle intervention on sexual function in men at high risk of type 2 diabetes are unclear.

objectiveTo assess the effect of testosterone treatment with a lifestyle intervention in men aged 50 to 74 years at high risk of, or newly diagnosed with, type 2 diabetes (via oral glucose tolerance test).

designA secondary analysis of the Testosterone for the Prevention of Type 2 Diabetes trial, a double-blind, placebo-controlled trial conducted across 6 Australian centers.

interventionsIntramuscular testosterone undecanoate (1000 mg) or placebo, 3 monthly for 2 years alongside a community-based lifestyle program. MAIN OUTCOMES: Sexual function measured using the International Index of Erectile Function (IIEF)-15 questionnaire.

resultsOf 1007 participants, 792 (79%) had complete International Index of Erectile Function-15 data. Baseline domain scores were inversely related to age and waist circumference, but unrelated to serum testosterone or estradiol levels. Testosterone treatment improved all 5 International Index of Erectile Function-15 domain scores, with stronger effects on sexual desire and orgasmic function in older men, and sexual desire in men with higher depression scores. Testosterone had no impact on depression. Independent of treatment, reductions in waist circumference were associated with improved erectile function, and reductions in depression scores correlated with better sexual function. Clinically significant improvement in erectile function and sexual desire occurred in 3% and 10% of men, respectively, and was inversely related to baseline function. Clinically significant improvement improvements in erectile function and sexual desire were greater in younger and older men respectively.

conclusionTestosterone treatment enhanced sexual desire and, to a lesser extent, erectile function, particularly in older men and those with higher waist circumference or depressive symptoms. Reduced waist circumference and depression independently improved sexual function.

Indexed as

AndrogensDiabetes Mellitus, Type 2Erectile DysfunctionSexual BehaviorTestosteroneAgedAustraliaDouble-Blind MethodHumansLibidoLife StyleMaleMiddle AgedPenile ErectionTreatment OutcomeAndrogensTestosteronetestosterone undecanoateclinical trialdiabetesobesitysexual functiontestosterone

Identifiers

PMID39928571
PMCPMC12187511

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.